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\bstract:
Introduction & Objective: AN,{L is a heterogeneous cancer that is caused by various pathologic
:rechanisms. \1osr adi.rlt patients rvitl-r AML die; even high doses of chemotherapy and allogeneic
-'icnr cell transplantation often lail to prevent recurrence. Chernokines are required by their
1'eceptors to niigrate leukocytes to inflammatory sites and secondarl' 11'mpiroid organs. 'fherefbre,
it is logical to p1a}, a lundamental role in the onset, progression. migration and survival of the
rumor. In addition, studies have shown that cancer cells undergo changes in the chemokine system.
Changing the c,vtokine netrvork can disrupt the activation of signaling pathu,'a1''s, overcotne
resistance to treatment. increase AML treatment, reduce treatment complicatiotrs" and improve
-\\,fL treatment outcornes. The CCR5 receptor. along with its ligands, has an indirect etl-ect on the
progression oicanccr b,v controlling immune response to the tumor. This receptol'can acceler;'rte
rlrrror grou,th and pla.v a significant role in metastasis. in this study. rve decided to investigate the
role of this recepttir in the tirst stage ol chemotherapy in patients rvith AN4L ri'ith nionocl'tic
difi-erentiation b_v stud,ving the CCR5 receptor with its ligands (CCL4. CCL3 and CCL-5).
Materials and Methods: ln a case-control stud-v, the samples were first matched accorclitrg to age
and blood samples u'ele collected liom the patient in the CBC tube and Chalat tLrbe u,'ith
satisiitction fi'om tlie patient" The expression of CCR-5 receptor r,vas tested by 11or,r' c-vtometr'1'
reehnit1Lir- ar.rd *ith RT-PCR technique. Also. tire concentration of CICL/I. CCl3 and CCL-5
cirenrokines in serur:r ol' patients heflole- and after chemotherapy as r.ve1l as in serunt of controi
groltp b"v El,lSA *as evaiuated. I)emographic inlbrmation weu obtained using a data colleclion
tbrm. Data anal,vsis uas performed tising SPSS version22.
Results: Ilased on the results of this stud1. the ler,'els oichemokine lignnrls in the serllm ol'the
patients before chemotherap\ \\erc signrlicanth higher than the coutrol groLtp. Al'ter chemokine
rhelap1,. the chemoliin.'ligani-1s uere sisnji'icantl] reduced. but CCL5 and CCL:I u'ere stiilhigh in
compalison i,lith tire healtirr ctrnir'o1 srollp. and sigrrificantlv reduced CCL3 lerels in the control
grollp, 'l'he expression oi CCR5 receptol' erpression in the patients atier lhe ltrst stage oi'
chemotherapy \,vas significantll loner than the control group, but did not show an1'' signi{icant
rlifference. On the other hanc1. usins the llorv cl.tometry technique. expression of C'CR5 on thc
ievel of lymphocytes in patients ll.as not significantly different from that of-the control group.
Ccnclusion: Cherlokine ligancls lvere very,' high in pre-chetnotherapv patients. but aller
.henrotlierapv. tlCL5 anct CCI-4 dicl not re;rch the baseline in control grolUr. but CL-L3 t'eachecl
baseline in comparisorl to control gror-rp. Afier the first stage of chemother,rp\'. the expression of
CCR5 receptor on the surf-ace of lyrnphocytes lvas not significantll' ditlerent tiom tliat of the
control group. Therelbre. it may be possible to use CCL5 and CCL4 inhibitors along u,ith
ihernt'rtherapy. maybe tavorable results can be obtained and prevention of relapse of the disease.
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